The weight loss drug craze is just beginning? Goldman Sachs: Lilly's stock price is expected to double again by 2028. The latest report released by Goldman Sachs predicts that although Lilly's stock has surged by over 50% this year, it is still possible to see a significant increase in the future. Goldman Sachs stated that as the GLP-1 weight loss drug craze continues, by 2028, as many as 68 million Americans, approximately 20% of the US population, may take the weight loss drug. This may drive the revenue of GLP-1 drugs to soar to $400 billion.